本文選題：腦膠質瘤 + 調(diào)強放射治療　； 參考：《福建醫(yī)科大學》2014年碩士論文

【摘要】：【目的】 分析腦膠質瘤術后調(diào)強放療患者生存情況，并探討影響腦膠質瘤患者的相關預后因素。 【方法】 回顧性分析2009年10月-2013年6月福建醫(yī)科大學附屬第一醫(yī)院放療科初次接受調(diào)強放射治療的腦膠質瘤術后患者。收集患者的年齡、性別、病理類型、腫瘤病理分級、是否同步放化療、腫瘤部位、腫瘤最大直徑、術前是否有癲癇、放療劑量、GFAP、Olig2、O6-甲基鳥嘌呤-DNA-甲基轉移酶（O6-methylguanine-DNA-methyltransferase,MGMT）的表達、Ki67水平的表達以及生存時間等資料。觀察所有患者1年、2年及3年的總生存率。采用Kaplan-Meier法計算生存率，Log-rank檢測比較各組間生存率的差別；采用Cox比例風險模型進行預后相關因素的研究。 【結果】 共有87例患者符合要求，其中隨訪到84例，隨訪率為96.5%（84/87），隨訪時間1-48個月，，中位隨訪時間14個月。全組患者中位生存時間36個月，共24例復發(fā)及23例死亡，1年、2年及3年總生存率分別為84.8%、67.5%和48.4%。單因素分析顯示年齡42歲組生存期優(yōu)于年齡≥42歲組（P=0.026）；無癲癇組生存期優(yōu)于有癲癇組（P=0.018）；Ki67＜10%組生存期優(yōu)于Ki67≥10%組(P=0.015)。病理級別越高生存期越短（P0.001）；Cox多因素分析顯示病理級別是影響患者生存期的獨立因素（P0.001）。 【結論】 病理級別是影響患者生存期的獨立因素，病理級別越高，預后越差。
[Abstract]:[purpose] To analyze the survival of patients with glioma treated by IMRT, and to explore the prognostic factors of glioma patients. [methods] From October 2009 to June 2013, the patients with glioma were treated with IMRT for the first time in the Department of radiotherapy, the first affiliated Hospital of Fujian Medical University. Age, sex, pathological type, pathological grade, concurrent radiotherapy and chemotherapy, tumor location, maximum diameter of tumor, epilepsy before operation were collected. Expression of O6-methylguanine-DNA-methyltransferase (MGMTT) and the expression of Ki67 and survival time of O6-methylguanine-DNA-methyltransferase (MGMTT) in patients with Olig2Olig2O6-methylguanine-DNA-methyltransferase. The 1 -, 2-and 3-year overall survival rates of all patients were observed. Kaplan-Meier method was used to calculate the survival rate and Log-rank test was used to compare the difference of survival rate among the groups, and Cox proportional risk model was used to study the prognostic factors. [results] A total of 87 patients met the requirements, of which 84 were followed up, with a follow-up rate of 96.50.84 / 87, with a follow-up time of 1-48 months and a median follow-up time of 14 months. The median survival time was 36 months. The overall survival rate of 1 year, 2 year and 3 years was 84.8% and 48.4%, respectively. Univariate analysis showed that the survival time of 42 years old group was better than that of Ki67 鈮

本文編號：1956461